Lipids and Liver: Nuevos mecanismos, biomarcadores de diagnóstico y progresión y dianas terapéuticas de enfermedad metabólica y Cáncer - GIC 21/087
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicaciones en colaboración con investigadoras/es de Hospital Universitario Marqués de Valdecilla (24)
2024
-
Feasibility and Short-Term Outcomes in Liver-First Approach: A Spanish Snapshot Study (the RENACI Project)
Cancers, Vol. 16, Núm. 9
-
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Hepatology, Vol. 79, Núm. 1, pp. 135-148
-
Textbook outcomes in the liver-first approach for colorectal liver metastases: prospective multicentre analysis
BJS Open, Vol. 8, Núm. 1
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology
2023
-
Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis
Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804
2022
-
Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation
American Journal of Transplantation, Vol. 22, Núm. 6, pp. 1671-1682
-
Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function
Journal of Hepatology, Vol. 76, Núm. 1, pp. 11-24
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
-
E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment
Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887
-
Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH
Journal of Hepatology, Vol. 75, Núm. 1, pp. 34-45
-
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
Molecular Metabolism, Vol. 53
2020
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
-
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
Nature Communications, Vol. 11, Núm. 1
-
Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly
Cell Metabolism, Vol. 31, Núm. 3, pp. 605-622.e10
2019
-
A survey of Heads of Surgery and Residents on accessibility and employment in liver transplant teams in Spain
Cirugia Espanola, Vol. 97, Núm. 10, pp. 560-567
-
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease
Molecular Metabolism, Vol. 29, pp. 40-54
2017
-
Deregulated neddylation in liver fibrosis
Hepatology, Vol. 65, Núm. 2, pp. 694-709
-
Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis
Gastroenterology, Vol. 152, Núm. 6, pp. 1449-1461.e7